LongRiver Investments is a venture capital firm focused on healthcare and deep tech, managing the full investment cycle from sourcing to exit with a top-down research framework. Founded in 2022 and based in Hong Kong, the firm closed its debut fund at $385 million.
They made 2 investments in the last 12 months. Their most common stage is series-a (60% of deals). Average disclosed round size is $80.4M (across 5 rounds with reported amounts).
Portfolio
4
Fund Size
$385M
Top Stage
Series A
Last 12 Mo
2
Team
Jayson Lee
Partner Head of Healthcare Investing
Liz Ge
Director of Finance & Portfolio Management
Sherry Lee
Executive Director Medical Device
Matteo Cui
Vice President
Sally Sun
Senior Vice President Biotech
Zhichen Song
Vice President Advanced Manufacturing
Lynne Lin
Senior Associate
Amy Fan
Associate
Alicia Zhang
Office Assistant
Claire Zhang
Senior Operations Manager & Head of PR
Jean Shi
General Legal Counsel
Jenea Xiao
Senior Manager of Finance & Portfolio Management
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| RRonovo | Series D | $67M | Sep 2025 |
 Ronovo Surgical | Series D | $67M | Sep 2025 |
 Rona | Series A | $35M | Jul 2024 |
| Rona | Series A | $200M | Jan 2024 |
 Rona Therapeutics | Series A | $33M | Apr 2022 |
Top Co-Investors
Last updated: 27 September 2026